Profil Financier
Jiang Rensheng & family occupe actuellement le rang #838 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $5.1 B (-$152 sur 24h).
Jiang Rensheng is the chairman of Shenzhen-listed vaccine firm Chongqing Zhifei Biological Products.
A longtime distribution partner of Merck, Zhifei won the Chinese sales rights to the U.S. pharma's HPV drug in 2018.
In 2023, Jiang took his antibody drug maker Chongqing Genrix Biopharmaceutical public on the Shanghai Stock Exchange.
Prior to striking out on his own, he worked as a primary school teacher and a government health official.
In 2024, Zhifei entered an exclusive partnership with British pharmaceutical giant GSK for the distribution of shingles vaccines and commercialization of Respiratory syncytial virus (RSV) vaccines in China.